Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.

Pigment cell & melanoma research - 1 May 2017

Silva Jillian M, Deuker Marian M, Baguley Bruce C, McMahon Martin

Abstract excerpt

Malignant conversion of BRAF- or NRAS-mutated melanocytes into melanoma cells can be promoted by PI3'-lipid signaling. However, the mechanism by which PI3'-lipid signaling cooperates with mutationally activated BRAF or NRAS has not been adequately explored. Using human NRAS- or BRAF-mutated melanoma cells that co-express mutationally activated PIK3CA, we explored the contribution of PI3'-lipid signaling to cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Melanoma
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to BRAF gene

Share to Mice, Nude

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Signal Transduction

Source

Open in PubMed Open full text

Identifiers

PMID: 28233937
DOI: 10.1111/pcmr.12586
PMCID: PMC5411292

Genes

BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PIK3CA-mutated melanoma cells rely on cooperative signaling through mTORC1/2 for sustained proliferation.PMID 28233937Read ↗

Navigating the Therapeutic Complexity of PI3K Pathway Inhibition in MelanomaSemantic proximity Read ↗

Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.Semantic proximity Read ↗

PI3′-Kinase Inhibition Forestalls the Onset of MEK1/2 Inhibitor Resistance in <i>BRAF</i> -Mutated MelanomaSemantic proximity Read ↗

PI3K Functions Downstream of Cdc42 to Drive Cancer phenotypes in a Melanoma Cell Line.Semantic proximity Read ↗

Beyond BRAF in melanoma.Semantic proximity Read ↗

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.Semantic proximity Read ↗

Concomitant Inhibition of PI3Kβ and BRAF or MEK in PTEN-Deficient/BRAF-Mutant Melanoma Treatment: Preclinical Assessment of SAR260301 Oral PI3Kβ-Selective Inhibitor.Semantic proximity Read ↗

BRAFV600E negatively regulates the AKT pathway in melanoma cell lines.Semantic proximity Read ↗

RICTOR involvement in the PI3K/AKT pathway regulation in melanocytes and melanoma.Semantic proximity Read ↗

Computational Modeling of PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer.Semantic proximity Read ↗

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.Semantic proximity Read ↗

Positive feedback loop between PI3K-Akt-mTORC1 signaling and the lipogenic pathway boosts Akt signaling: induction of the lipogenic pathway by a melanoma antigen.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.